GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Cyclically Adjusted Price-to-FCF

IntelliPharmaCeutics International (TSXV:IPCI) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF falls into.



IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

IntelliPharmaCeutics International's Cyclically Adjusted FCF per Share for the quarter that ended in Aug. 2023 is calculated as:

For example, IntelliPharmaCeutics International's adjusted Free Cash Flow per Share data for the three months ended in Aug. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=0.01/125.3885*125.3885
=0.010

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201311 -0.964 97.182 -1.244
201402 0.071 98.051 0.091
201405 0.329 99.394 0.415
201408 -0.806 99.315 -1.018
201411 -0.784 99.078 -0.992
201502 -0.085 99.078 -0.108
201505 -0.674 100.263 -0.843
201508 -0.757 100.579 -0.944
201511 -0.746 100.421 -0.931
201602 -1.035 100.421 -1.292
201605 -0.704 101.765 -0.867
201608 -1.791 101.686 -2.208
201611 0.159 101.607 0.196
201702 -1.068 102.476 -1.307
201705 -0.783 103.108 -0.952
201708 -0.682 103.108 -0.829
201711 -0.804 103.740 -0.972
201802 -0.590 104.688 -0.707
201805 -0.110 105.399 -0.131
201808 -0.390 106.031 -0.461
201811 -1.144 105.478 -1.360
201902 -0.234 106.268 -0.276
201905 -0.115 107.927 -0.134
201908 -0.066 108.085 -0.077
201911 -0.014 107.769 -0.016
202002 -0.003 108.559 -0.003
202005 0.004 107.532 0.005
202008 0.037 108.243 0.043
202011 -0.034 108.796 -0.039
202102 0.000 109.745 0.000
202105 -0.033 111.404 -0.037
202108 -0.052 112.668 -0.058
202111 -0.013 113.932 -0.014
202202 -0.022 115.986 -0.024
202205 -0.013 120.016 -0.014
202208 -0.011 120.569 -0.011
202211 -0.006 121.675 -0.006
202302 -0.001 122.070 -0.001
202305 0.004 124.045 0.004
202308 0.010 125.389 0.010

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IntelliPharmaCeutics International  (TSXV:IPCI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines